ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO628

Pseudohypobicarbonatemia Induced by Severe Hypertriglyceridemia

Session Information

Category: Fluid and Electrolytes

  • 902 Fluid and Electrolytes: Clinical

Authors

  • Varghese, Vipin, University of Queensland - Ochsner Clinical School, New Orleans, Louisiana, United States
  • Velez, Juan Carlos Q., University of Queensland - Ochsner Clinical School, New Orleans, Louisiana, United States
Background

Reports of falsely low serum carbon dioxide (sCO2) concentration, i.e., pseudohypobicarbonatemia (psHypoHCO3-) in patients with severe hypertriglyceridemia (hyperTG) have emerged. This phenomenon results from lipid interference in some spectrophotometric analyzers. Our aim was to assess the magnitude and implications of psHypoHCO3- in a tertiary care hospital.

Methods

We searched for cases of serum triglycerides (TG) > 1000 mg/dL with a concomitant (measured <24 hrs apart) sCO2, between 2017 and 2018. We extracted those with sCO2 ≤ 12 mEq/L to focus on the more clinically relevant cases. Each measured sCO2 was compared with the calculated bicarbonate (HCO3-) from an arterial blood gas (ABG) obtained within 6 hrs of the venous blood draw. PsHypoHCO3- was defined as: erroneous HCO3- (eHCO3-) gap = (calculated HCO3- - measured sCO2) > 5 mEq/L.

Results

We identified 1698 events (652 patients) of TG > 1000 mg/dL and a sCO2 measured on the same day. TG inversely correlated with sCO2 (R=-0.38, p=0.00001). We found 179 events (59 patients) with sCO2 < 12 mEq/L. In 104 of those, an ABG was either not available or performed > 6 hrs apart from the venous blood draw. The remaining 75 events included 30 instances (11 patients) of true hypobicarbonatemia and 45 instances (24 patients) of psHypoHCO3-. Among those with psHypoHCO3-, the median values of sCO2, calculated HCO3-, anion gap and eHCO3- gap were 8 (<5 – 12), 20 (10 - 28), 21 (15 – 29) and 13 (5 – 19) mEq/L, respectively, whereas the median pH was 7.37 (7.14 - 7.56). True metabolic acidosis was either absent (42%) or spuriously magnified (58%). TG directly correlated with the eHCO3- gap (R=0.59, p=0.00004). Acute pancreatitis (56%) and diabetic ketoacidosis (38%) were the most common concomitant disorders but they did not fully account for the eHCO3- gap in the psHypoHCO3- cases. Additionally, unnecessary HCO3- therapy was initiated in 16% and serum lactate was measured in 80% of the psHypoHCO3- events (lactate was normal in 72%).

Conclusion

Severe hyperTG can lead to spuriously low sCO2. The degree of hyperTG correlates with the magnitude of PsHypoHCO3-. Clinicians and laboratory personnel should be aware of this phenomenon to prevent incorrect interpretation of acid-base status and medical mismanagement.